Plataforma BIOBADASER III

Registro Español de Acontecimientos Adversos de Terapias Dirigidas en Enfermedades Reumáticas

Biobadaser Fase III

Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases

02/12/2024

Adrián Quevedo-Rodríguez, Lucia Otero-Varela, Fernando Sánchez-Alonso, Yanira Pérez-Vera, Javier Manero-Ruiz, Cristina Campos-Fernández, Sara Manrique-Arija, Paloma Vela-Casasempere, Antonio Mera-Varela, César Díaz, Atusa Movasat, Blanca Garcia-Magallon, Inmaculada Ros-Vilamajó, Carolina Perez-Garcia and Isabel Castrejon, and BIOBADASER working group.

ACR 2024

https://acrabstracts.org/abstract/evaluation-of-the-survival-and-safety-of-biologic-and-targeted-synthetic-dmard-in-patients-with-difficult-to-treat-ra-using-real-world-data-from-a-nationwide-registry-of-rheumatic-diseases/